Abingworth management ltd - see notes investment history in Supernus pharmaceuticals inc

Filed on 2012-05-08 by Abingworth Management Ltd SEC CIK 1291892 Form 4

Accession 0001140361-12-023735.txt Sec File: edgar/data/1291892/0001140361-12-023735-index.htm

2012-05-04 Abingworth Management Ltd (CIK 1291892) through See Notes

Invested in Supernus Pharmaceuticals Inc sold 10000000 shares at $1.00 remaining shares owned 0

Series A Convertible Preferred Stock Supernus Pharmaceuticals Inc Supn exercise date 2006-02-14 underlying security shares 2500000 underlying security title Common Stock

f2 abingworth management ltd (the "reporting person") is the investment manager to a number of investment funds that include abingworth bioventures iv lp ("abv iv") and abingworth bioventures iv executives lp ("abv iv execs," and together with abv iv, the "abingworth funds"). on may 4, 2012, abv iv purchased 1,090,650 shares of common stock and abv iv execs purchased 9,350 shares of common stock.
f3 following the transactions reported herein, abv iv holds 3,569,400 shares of common stock and abv iv execs holds 30,600 shares of common stock. the reporting person may be deemed to beneficially own the securities reported herein indirectly through the abingworth funds. the reporting person's interest in the securities reported herein is limited to the extent of its pecuniary interest, if any, in the abingworth funds. this report shall not be deemed an admission that the reporting person, either abingworth fund or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.
f1 the 10,000,000 shares of series a convertible preferred stock, par value $0.001 per share ("preferred stock"), of supernus pharmaceuticals, inc. (the "issuer"), converted automatically into 2,500,000 shares of common stock, par value $0.001 per share ("common stock"), of the issuer, without the payment to the issuer of any consideration, upon the closing of the issuer's initial public offering on may 4, 2012. the shares of preferred stock did not have an expiration date.


Filed on 2012-05-08 by Abingworth Management Ltd SEC CIK 1291892 Form 4

Accession 0001140361-12-023735.txt Sec File: edgar/data/1291892/0001140361-12-023735-index.htm

2012-05-04 Abingworth Management Ltd (CIK 1291892) through See Notes

Invested in Supernus Pharmaceuticals Inc bought 1100000 shares at $5.00 remaining shares owned 3600000

Common Stock 0001 Par Value Per Share Supernus Pharmaceuticals Inc Supn Transaction code: P Open market or private purchase of securities

f2 abingworth management ltd (the "reporting person") is the investment manager to a number of investment funds that include abingworth bioventures iv lp ("abv iv") and abingworth bioventures iv executives lp ("abv iv execs," and together with abv iv, the "abingworth funds"). on may 4, 2012, abv iv purchased 1,090,650 shares of common stock and abv iv execs purchased 9,350 shares of common stock.
f3 following the transactions reported herein, abv iv holds 3,569,400 shares of common stock and abv iv execs holds 30,600 shares of common stock. the reporting person may be deemed to beneficially own the securities reported herein indirectly through the abingworth funds. the reporting person's interest in the securities reported herein is limited to the extent of its pecuniary interest, if any, in the abingworth funds. this report shall not be deemed an admission that the reporting person, either abingworth fund or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.


Filed on 2012-05-08 by Abingworth Management Ltd SEC CIK 1291892 Form 4

Accession 0001140361-12-023735.txt Sec File: edgar/data/1291892/0001140361-12-023735-index.htm

2012-05-04 Abingworth Management Ltd (CIK 1291892) through See Notes

Invested in Supernus Pharmaceuticals Inc bought 2500000 shares remaining shares owned 2500000

Common Stock 0001 Par Value Per Share Supernus Pharmaceuticals Inc Supn Transaction code: C Conversion of derivative security (usually options)

f1 the 10,000,000 shares of series a convertible preferred stock, par value $0.001 per share ("preferred stock"), of supernus pharmaceuticals, inc. (the "issuer"), converted automatically into 2,500,000 shares of common stock, par value $0.001 per share ("common stock"), of the issuer, without the payment to the issuer of any consideration, upon the closing of the issuer's initial public offering on may 4, 2012. the shares of preferred stock did not have an expiration date.
f2 abingworth management ltd (the "reporting person") is the investment manager to a number of investment funds that include abingworth bioventures iv lp ("abv iv") and abingworth bioventures iv executives lp ("abv iv execs," and together with abv iv, the "abingworth funds"). on may 4, 2012, abv iv purchased 1,090,650 shares of common stock and abv iv execs purchased 9,350 shares of common stock.
f3 following the transactions reported herein, abv iv holds 3,569,400 shares of common stock and abv iv execs holds 30,600 shares of common stock. the reporting person may be deemed to beneficially own the securities reported herein indirectly through the abingworth funds. the reporting person's interest in the securities reported herein is limited to the extent of its pecuniary interest, if any, in the abingworth funds. this report shall not be deemed an admission that the reporting person, either abingworth fund or any other person is the beneficial owner of the securities reported herein for purposes of section 16 of the securities exchange act of 1934, as amended, or for any other purpose.